RESEARCH TRIANGLE PARK, N.C., July 6, 2026
Opus Genetics announced that the U.S. Food and Drug Administration (FDA) has aligned with the company’s proposed registrational Phase 3 clinical trial design for OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease (IRD), following a successful Type B Rare Disease Evidence Principles (RDEP) meeting. The FDA confirmed key elements of the pivotal study, including enrollment of eight participants, bilateral treatment, a six-month natural history run-in period, and the use of retinal sensitivity measured by microperimetry as the primary efficacy endpoint. Importantly, the agency indicated that the company may submit a Biologics License Application (BLA) based on six-month efficacy data while providing 12-month durability data during the regulatory review process. Opus expects to begin dosing patients in the Phase 3 trial during the fourth quarter of 2026, with seven of the eight planned participants already enrolled in the run-in period.
Phase 3 Trial Builds on Encouraging Early Clinical Results
The registrational study has been designed with more than 90% statistical power to detect a clinically meaningful improvement of at least 7 decibels (dB) in retinal sensitivity across the central 16 microperimetry test loci. This endpoint is supported by results from the ongoing Phase 1/2 clinical trial, where evaluable participants demonstrated an average improvement of approximately 10.5 dB, indicating meaningful gains in visual function. The Phase 1/2 study has also shown a favorable safety profile, with pediatric patients experiencing substantial improvements in cone-mediated vision and adult participants maintaining durable improvements in cone sensitivity and visual function for up to 18 months. No ocular serious adverse events or dose-limiting toxicities have been reported to date, providing continued confidence in the therapy’s clinical development.
OPGx-LCA5 Targets a Severe Form of Inherited Childhood Blindness
OPGx-LCA5 is an adeno-associated virus 8 (AAV8)-based gene therapy designed to deliver a functional copy of the LCA5 gene directly to retinal cells in patients with biallelic LCA5 mutations. These mutations cause one of the most severe forms of Leber congenital amaurosis (LCA), leading to profound vision loss beginning early in childhood and currently lacking any approved treatment options. Scientific studies have demonstrated that many patients retain retinal structure despite severe functional vision loss, creating an opportunity for gene replacement therapy to restore visual function. The investigational therapy has received multiple FDA regulatory incentives, including Rare Pediatric Disease Designation, Orphan Drug Designation, Regenerative Medicine Advanced Therapy (RMAT) Designation, and acceptance into the FDA’s Rare Disease Evidence Principles (RDEP) program, reflecting both the rarity of the disease and the significant unmet medical need.
Advertisement
Regulatory Milestone Supports Potential Accelerated Development Pathway
The FDA’s agreement on the registrational strategy provides Opus Genetics with a clearly defined regulatory pathway toward potential approval of OPGx-LCA5. Company leadership noted that the ability to submit a BLA based on six-month efficacy data, while providing longer-term durability results during the review process, could significantly accelerate access to treatment for patients with LCA5-associated inherited retinal disease. In addition to the potential for regulatory approval, the program may also qualify for a Priority Review Voucher, representing an important strategic asset for the company. Beyond OPGx-LCA5, Opus Genetics continues to expand its ophthalmology pipeline with additional AAV-based gene therapy programs targeting several inherited retinal disorders, reinforcing its long-term commitment to developing one-time genetic treatments aimed at restoring vision and preventing blindness in patients with rare retinal diseases.
Source: Opus Genetics press release
